Tailoring therapy for heart failure: The pharmacogenomics of adrenergic receptor signaling

Grazia Daniela Femminella, Vincenzo Barrese, Nicola Ferrara, Giuseppe Rengo

Research output: Contribution to journalArticle


Heart failure is one of the leading causes of mortality in Western countries, and β-blockers are a cornerstone of its treatment. However, the response to these drugs is variable among individuals, which might be explained, at least in part, by genetic differences. Pharmacogenomics is the study of genetic contributions to drug response variability in order to provide evidence for a tailored therapy in an individual patient. Several studies have investigated the pharmacogenomics of the adrenergic receptor system and its role in the context of the use of β-blockers in treating heart failure. In this review, we will focus on the most significant polymorphisms described in the literature involving adrenergic receptors and adrenergic receptor-related proteins, as well as genetic variations influencing β-blocker metabolism.

Original languageEnglish
Pages (from-to)267-273
Number of pages7
JournalPharmacogenomics and Personalized Medicine
Publication statusPublished - Sep 9 2014


  • Adrenergic system
  • Functional recovery
  • Polymorphisms
  • β-Blockers

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology

Fingerprint Dive into the research topics of 'Tailoring therapy for heart failure: The pharmacogenomics of adrenergic receptor signaling'. Together they form a unique fingerprint.

  • Cite this